多发性骨髓瘤早期死亡的预测因素:来自澳大利亚与新西兰骨髓瘤及相关疾病登记处(MRDR)的结果
该前瞻性队列研究纳入2011年7月至2020年3月在36家机构登记的2377例新诊断多发性骨髓瘤患者,早期死亡定义为诊断后12个月内任何原因死亡。216例(9.1%)在12个月内死亡,119例(4.5%)在6个月内死亡;多因素回归中年龄、ECOG体能状态、血清白蛋白、心脏病和国际分期系统为早期死亡的独立预测因素。
要点
- 2377例新诊断多发性骨髓瘤患者中,216例(9.1%)在诊断后12个月内死亡,119例(4.5%)在6个月内死亡。
- 多因素回归中年龄OR 1.07、ECOG体能状态OR 1.50、血清白蛋白OR 0.95、心脏病OR 1.96、国际分期系统OR 1.40为早期死亡的独立预测因素。
- 有原发死因记录者中,151例(78%)为疾病相关,13例(7%)为感染,29例(15%)为其他;38%的患者将感染列为死亡促进因素。
核心结论
- 在新药时代,新诊断多发性骨髓瘤患者12个月内早期死亡率为9.1%,年龄、ECOG体能状态、血清白蛋白、心脏病和国际分期系统为早期死亡的独立预测因素。
研究设计与样本
- 前瞻性队列研究,纳入2011年7月至2020年3月在36家机构澳大利亚与新西兰骨髓瘤及相关疾病登记处(MRDR)登记的全部新诊断多发性骨髓瘤患者,共2377例;早期死亡定义为诊断后12个月内任何原因死亡。
主要发现
- 2377例患者中位(四分位距)年龄为67.4(58.9-74.60)岁,60%为男性;216例(9.1%)在12个月内死亡,119例(4.5%)在6个月内死亡。
- 多因素回归调整后早期死亡的独立预测因素包括年龄(OR 1.07,95%CI 1.05-1.08;p < 0.001)、ECOG体能状态(OR 1.50,95%CI 1.26-1.79;p < 0.001)、血清白蛋白(OR 0.95,95%CI 0.93-0.98;p < 0.001)、心脏病(OR 1.96,95%CI 1.35-2.86;p < 0.001)和国际分期系统(OR 1.40,95%CI 1.07-1.82;p = 0.01)。
- 在有原发死因记录的患者中,151例(78%)为疾病相关,13例(7%)为感染,29例(15%)为其他;38%的患者将感染列为死亡促进因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The frequency and causes of early mortality in patients with newly diagnosed multiple myeloma (NDMM) have not been well described in the era of novel agents. We investigated early mortality in a prospective cohort study of all patients with NDMM registered on the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) at 36 institutions between July 2011 and March 2020. Early mortality was defined as death from any cause within the first 12 months after diagnosis. A total of 2377 patients with NDMM were included in the analysis, with a median (interquartile range) age of 67.4 (58.9-74.60 years, and 60% were male. Overall, 216 (9.1%) patients died within 12 months, with 119 (4.5%) having died within 6 months. Variables that were independent predictors of early mortality after adjustment in multivariable regression included age (odds ratio [OR] 1.07, 95% confidence interval [CI] 1.05-1.08; p < 0.001), Eastern Cooperative Oncology Group performance status (OR 1.50, 95% CI 1.26-1.79; p < 0.001), serum albumin (OR 0.95, 95% CI 0.93-0.98; p < 0.001), cardiac disease (OR 1.96, 95% CI 1.35-2.86; p < 0.001) and International Staging System (OR 1.40, 95% CI 1.07-1.82; p = 0.01). For those with a primary cause of death available, it was reported as disease-related in 151 (78%), infection 13 (7%), other 29 (15%). Infection was listed as a contributing factor for death in 38% of patients.
引用
- McQuilten Z, Wellard C, Moore E, et al. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Br J Haematol. 2022. PMID: 35818641. doi:10.1111/bjh.18324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。